While Foolish readers know all too well that a good turnaround story can
drive excellent shareholders, sometimes discretion is the better part
of valor and it makes more sense to just get out and move on. That is
the attitude of Johnson & Johnson (NYSE: JNJ )
with respect to its Ortho Clinical Diagnostics, or OCD, business, with
the company openly acknowledging that it has begun discussions to sell
this long-underperforming unit.
Continue here for the full article:
http://www.fool.com/investing/general/2013/09/12/johnson-johnson-looks-to-turn-the-fading-ortho-dia.aspx
No comments:
Post a Comment